BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Leucovorin 50 mg/5 mL 500 mg/50 mL (Hospira) (F)(PFL) no preservative[1]	N/A	10 mg/mL[1]	50 mg: discard unused portion[2] 500 mg: 8 h[1]	syringe[3]	7 d F,[3] 48 h RT[3,4]	
				0.05-10 mg/mL NS, D5W, Ringer's, LR, D10W, D5NS[1,2] (e.g., 50-250 mL*)	**NS**, D5W, LR, Ringer's: 24 h RT[1] D10W, D5-NS: 8 h RT[1]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Leucovorin 50 mg/5 mL 500 mg/50 mL (Teva) (F)(PFL) no preservative[5]	N/A	10 mg/mL[1]	discard unused portion[1]	syringe	8 h[6,7]	
				0.4 - 4.8 mg/mL **NS**, D5W[8] (e.g., 50-250 mL*)	72 h **F**, RT[8]	
				0.06 - 0.4 mg/mL **NS**, D5W[5]	NS: 24 h RT[5] D5W: 12 h RT[5]	
				0.06 - 1 mg/mL Ringer's, Lactated Ringer's, D10W, D10NS[5]	Ringer's, LR: 24 h RT[5] D10W: 12 h RT[5] D10NS: 6 h RT[5]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Leucovorin 50 mg/5 mL 500 mg/50 mL (Pfizer) (F)(PFL) no preservative[9]	N/A	10 mg/mL[9]	8 h[9]	syringe	8 h RT[9]	
				0.05 – 10 mg/mL **NS**, D5W, LR, Ringer's, D10W, D5NS[9] (e.g., 50-250 mL*)	**NS**, D5W, LR, Ringer's: 24 h RT[9] D10W, D5NS: 8 h RT[9]	
Mechlorethamine 10 mg (Ovation/Merck) (RT,PFL) no preservative[10]	do NOT use if discoloured or water droplets form in vial before reconstitution[10] 10 mL SWI or NS[10] record time of reconstitution	1 mg/mL[10]	use within 4 h of reconstitution RT[7,11]	syringe[10]	complete administration within 4 h of reconstitution RT[7,10,11]	
				100 mL NS[10,12]	complete administration within 4 h of reconstitution RT[7,10,12]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Melphalan 50 mg (GSK) (RT)(PFL) no preservative[13]	10mL supplied diluent[13] immediately after adding diluent, shake vigorously[13] record time of reconstitution	5 mg/mL[13]	2 h RT[13] **do NOT refrigerate**	0.1 – 0.45 mg/mL in **NS** only[13] (e.g., greater than 45 mg and less than or equal to 110 mg in 250 mL NS)*	complete administration within 60 min from time of initial reconstitution at RT[11]	
Mesna 1000 mg/10mL (Fresenius Kabi) (RT) preservative[14]	N/A	100 mg/mL[14]	14 d **F,** RT[7,14]	Greater than or equal to 1mg/mL[14] **NS** or D5W	48 h F, 24 h RT[14]	
Methotrexate 50 mg/2mL 500 mg/20mL 1 g/40mL 5 g/200mL (Hospira) (RT)(PFL) no preservative[15]	N/A	25 mg/mL[15]	50mg: discard unused portion[15] 500mg, 1 g, 5 g: 8 h **F,** RT[15]	syringe	2 d **F**, RT[11,16,17]	- for high-dose regimens (e.g., 1-12 g/m^2 as a single dose)[18-22]: use preservative-free methotrexate[11] - do not use for IT injection
				0.4–2 mg/mL[23] 100 mL* **NS**, D5W	24 h RT[23]	
				high dose (e.g., 1-12 g/m^2 as a single dose)[18-22]: 1000 mL* NS	24 h RT[2,23,24]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Methotrexate **IT Injection**[15]: Only preservative free methotrexate may be administered by the intrathecal route[15] 50 mg/2mL[25] (Hospira) (RT)(PFL) no preservative[15]	N/A	25 mg/mL[15]	discard unused portion[15]	qs to 6 mL with preservative free NS[26]	use within 4 h of initial puncture[7,11]	- auxiliary label[27]: "IT" - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag[27]
Methotrexate 50 mg/2mL 500 mg/20mL (Hospira) (RT)(PFL) preservative[15]	N/A	25 mg/mL[15]	14 d F[28,29]	syringe 0.4–2 mg/mL[23] 100 mL* **NS**, D5W[15]	14 d **F**[4,16] 24 h RT[28]	- for high-dose regimens (e.g., 1-12 g/m^2 as a single dose)[18-22]: use preservative-free methotrexate[11] - do not use for IT injection
Mitomycin 20 mg (Accord) (RT)(PFL) no preservative[30]	40 mL SWI[30] shake well[30]	0.5 mg/mL[30]	6 h RT, 72 h F[30] **(PFL)[30]	syringe	6 h RT, 72 h F[30] **(PFL)[30]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Mitomycin <u>intravesical</u> 20 mg (Accord) (RT)(PFL) no preservative[30]	40 mL SWI[30] shake well[30]	0.5 mg/mL[30]	6 h RT, 72 h F[30] **(PFL)[30]	syringe	6 h RT, 72 h F[30] **(PFL)[30]	
	10 mL SWI[31] shake well[30]	2 mg/mL[31]	use immediately after preparation to prevent precipitation[32]	syringe	use immediately after preparation to prevent precipitation[32]	- may precipitate due to low solubility[32,33] - do NOT refrigerate[32]
Mitomycin <u>intraperitoneal</u> 20 mg (Accord) (RT)(PFL) no preservative[30]	40 mL SWI[30] shake well[30]	0.5 mg/mL[30]	6 h RT, 72 h F[30] **(PFL)[30]	0.02-0.04 mg/mL[30] **NS**, sodium lactate[30]	NS: 3 h RT, 18 h F[30] sodium lactate: 3 h RT, 6 h F[30]	
Mitomycin 20 mg (Teva) (RT)(PFL) no preservative[34]	40 mL SWI[34] shake well[34]	0.5 mg/mL[34]	6 h RT, 72 h F[34] **(PFL)[34]	syringe	6 h RT, 72 h F[34] **(PFL)[34]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Mitomycin <u>intravesical</u> 20 mg (Teva) (RT)(PFL) no preservative[34]	40 mL SWI[34] shake well[34]	0.5 mg/mL[34]	6 h RT, 72 h F[34] **(PFL)[34]	syringe	6 h RT, 72 h F[34] **(PFL)[34]	
	10 mL SWI[31] shake well[34]	2 mg/mL[31]	use immediately after preparation to prevent precipitation[32]	syringe	use immediately after preparation to prevent precipitation[32]	- may precipitate due to low solubility[32,33] - do NOT refrigerate[32]
Mitomycin <u>intraperitoneal</u> 20 mg (Teva) (RT)(PFL) no preservative[34]	40 mL SWI[34] shake well[34]	0.5 mg/mL[34]	6 h RT, 72 h F[34] **(PFL)[34]	0.02-0.04 mg/mL[34] **NS**, sodium lactate[34]	NS: 6 h RT, 18 h F[34] sodium lactate: 6 h RT, F[34]	
mitoXANTRONE 20 mg/10 mL (Fresenius Kabi) (RT) no preservative[35]	N/A	2 mg/mL[35]	discard unused portion[35]	**NS,** D5W[35] Greater than or equal to *50 mL[35]	24 h RT[35]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
mitoXANTRONE 20 mg/10 mL 25 mg/12.5 mL (Hospira) (RT)(PFL) no preservative[36]	N/A	2 mg/mL[36]	discard unused portion[36]	0.2-0.6 mg/mL[36] **NS**, D5W[36] Greater than or equal to *50 mL[36]	NS: 24 h **F**, RT[36] **(PFL)[36]	
mitoXANTRONE 20 mg/10 mL (Teva/Novopharm) (RT)(PFL) no preservative[37]	N/A	2 mg/mL[37]	discard unused portion[37]	Greater than or equal to *50 mL **NS**, D5W[37]	24 h RT[37] **(PFL)[38]	
Nivolumab 40 mg/4 mL 100 mg/10 mL (BMS) (F)(PFL) do not shake no preservative[39]	N/A	10 mg/mL[39]	discard unused portion[39]	1-10 mg/mL[39] **NS**, D5W[39] mix by gentle inversion[39]	complete administration within 8 h RT or 24 h F[40]	- administer with a 0.2 to 1.2 micron in-line filter[39] - discard if cloudy or has pronounced colour change (should be clear to pale yellow)[39]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
oBINutuzumab 1000 mg/40 mL (Hoffman-La Roche) (F)(PFL)** do not shake no preservative[41]	N/A	25 mg/mL[41]	discard unused portion[2]	100 mg: in 100 mL **NS**[41] 900 mg: in 250 mL **NS**[41] 1000 mg: in 250 mL **NS**[41]	**24 h F**, 48 h RT[41,42]	-once removed from the fridge, diluted product is stable for an additional 48 h RT[41,42] - do NOT shake[41] - do NOT use dextrose containing solutions[41]
Octreotide 50 mcg/mL 100 mcg/mL 500 mcg/mL (Omega) (F)(PFL) no preservative[43]	N/A	50 mcg/mL[43] 100 mcg/mL[43] 500 mcg/mL[43]	Use within 4 h[43]	NS[43] volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/hour[43]	24 h RT[43]	
Octreotide multidose vial: 1000 mcg/5 mL (Omega) (F)(PFL) preservative[43]	N/A	200 mcg/mL[43]	15 d F[43]	NS[43] volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/hour[43]	24 h RT[43]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Octreotide 50 mcg/mL 100 mcg/mL 500 mcg/mL (Teva/Novopharm) (F)(PFL) no preservative[44]	N/A	50 mcg/mL[44] 100 mcg/mL[44] 500 mcg/mL[44]	discard unused portion[44]	SC syringe[44]	use within 4 h[44]	
				infusion: NS[44]	24 h RT[44]	
Octreotide multidose vial: 1000 mcg/5 mL (Teva/Novopharm) (F)(PFL) preservative[44]	N/A	200 mcg/mL[44]	14 d F[29,44]	SC syringe	use within 14 d F[29,44]	
				infusion: NS[44]	24 h RT[44]	
Octreotide (SANDOSTATIN®) 1000 mcg/5 mL (Novartis) (F)(PFL) preservative[45]	N/A	200 mcg/mL[45]	discard unused portion[46]	50–200 mL NS[11,47,48] SC infusion: adjust volume to ensure infusion rate of 25 mcg/h[47]	24 h RT[47]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Octreotide (SANDOSTATIN®) 50 mcg/1 mL 100 mcg/1 mL 500 mcg/1 mL (Novartis) (F)(PFL) no preservative[45]	N/A	50 mcg/mL 100 mcg/mL 500 mcg/mL[45]	discard unused portion[47]	50-100 mL[11,48] NS[47] SC infusion: adjust volume to ensure infusion rate of 25 mcg/h[47]	24 h RT[47]	
Octreotide (SANDOSTATIN LAR®) 10 mg 20 mg 30 mg (Novartis) (F)(PFL) no preservative[46]	2 mL supplied diluent gently run 2 mL down sides of the vial; do NOT disturb for 2–5 min, then swirl moderately[47] record time of reconstitution	10 mg: 5 mg/mL 20 mg: 10 mg/mL 30 mg: 15 mg/mL[47]	discard unused portion[47]	deep intragluteal administration only[47]	use within 4 h of initial reconstitution[7,47]	- do NOT shake

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
oFAtumumab 100 mg/ 5 mL 1000 mg/50 mL (GlaxoSmithKline) (F)(PFL) no preservative[49]	N/A	20 mg/mL[49]	discard unused portion[2]	1000 mL NS[49] or alternatively, 2000 mg doses may be supplied in 2 x 500 mL NS[49] withdraw volume from bag equal to volume of drug to be added[49]	48 h RT[49]	- administer with 0.2 micron in-line filter[49] - do NOT shake; mix by slow inversion to avoid formation of foam[49] - solution may contain a small quantity of drug particles; do not administer if solution is cloudy or discoloured[49]
Olaratumab 500 mg/50 mL (Lilly) (F)(PFL) do not shake no preservative[50]	N/A	10 mg/mL[50]	discard unused portion[2,50]	dilute to a final volume of 250 mL NS[50] do NOT use D5W or other dextrose containing solutions[50] gently invert to mix[50]	complete administration within 24 h F, plus an additional 12 h RT[50]	- do NOT shake[50]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Oxaliplatin 50 mg 100 mg (Actavis) (RT)(PFL) no preservative[51]	50 mg: 10 mL SWI, D5W[51] 100 mg: 20 mL SWI, D5W[51]	5 mg/mL[51]	discard unused portion[51]	250-500 mL D5W (0.2-0.7 mg/mL)[51] do NOT use NS or other chloride-containing solutions[51] do NOT use aluminum-containing needle and syringe[51]	0.2-2 mg/mL: 24 h F[51]	- do NOT use aluminum-containing needle, syringe or tubing[51]
Oxaliplatin 50 mg/10 mL 100 mg/20 mL 200 mg/40 mL (Hospira/Pfizer) (RT) no preservative[52]	N/A	5 mg/mL[52]	discard unused portion[52]	250-500 mL D5W (0.2-0.7 mg/mL[52] do NOT use NS or other chloride-containing solutions[53] do NOT use aluminum-containing needle and syringe[53]	0.2-0.4 mg/mL: 24 h RT or 5 d F plus an additional 8 h RT[52,54] 0.5–2 mg/mL: 24 h RT or 14 d F plus an additional 8 h RT[52,54]	- do NOT use aluminum-containing needle, syringe or tubing[52]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Oxaliplatin 50 mg/10 mL 100 mg/20 mL 200 mg/40 mL (sanofi-aventis) (RT)(PFL) no preservative[55]	N/A	5 mg/mL[55]	discard unused portion[55]	250–500 mL D5W[55] (0.2-2 mg/mL)[55,56] do NOT use NS or other chloride-containing solutions[55] do NOT use aluminum-containing needle and syringe[55]	0.2-1.3 mg/mL: 48 h RT, 14 d F[4,56,57] 1.3-2 mg/mL: 24 h RT, 48 h F[55]	- do NOT use aluminum-containing needle, syringe or tubing[55]
Oxaliplatin 50 mg/10 mL 100 mg/20 mL 150 mg/30 mL 200 mg/40 mL (Sandoz) (RT)(PFL) no preservative[53]	N/A	5 mg/mL[53]	2 d **F**, RT[2,58]	0.2-0.7 mg/mL[53] 250-500 mL D5W[53] do NOT use NS or other chloride-containing solution[53] do NOT use aluminum-containing needle and syringe[53]	0.2-2 mg/mL: 24 h RT, 48 h F[53]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Oxaliplatin 50 mg/10 mL 100 mg/20 mL 200 mg/40 mL (Teva) (RT)(PFL) no preservative[59]	N/A	5 mg/mL[59]	discard unused portion[59]	250-500 mL D5W (0.2-0.7 mg/mL)[59] do **NOT** use NS or other chloride-containing solution[59] do NOT use aluminum-containing needle and syringe[59]	0.2-2 mg/mL: 24 h RT, 48 h F[59]	- do NOT use aluminum-containing needle, syringe or tubing[59]
PACLitaxel 30 mg/5 mL 100 mg/16.7 mL 300 mg/50 mL (Accord) (RT)(PFL) no preservative[60]	N/A	6 mg/ mL[60]	30 mg: 48 h RT[2,60] 100 mg: 48 h RT[2,60] 300 mg: 24 h RT[60]	0.3-1.2 mg/mL in **NS**, D5W, D5NS, D5LR[60] (e.g., 100-1000 mL)*	complete administration within 27 h RT[60]	- use non-DEHP bag and tubing with 0.22 micron in-line filter[60] - avoid excessive shaking[60]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
PACLitaxel 30 mg/5 mL 100 mg/16.7 mL 300 mg/50 mL (Biolyse) (RT)[61] no preservative[62]	N/A	6 mg/mL[62]	48 h RT[2,63]	0.3-1.2 mg/mL in **NS,** D5W[62] (e.g., 100-1000 mL)*	complete administration within 27 h RT[62,64]	- use non-DEHP bag and tubing with 0.22 micron in-line filter[62]
				0.1 mg/mL in **NS**[65]	44 h **F**, RT[65]	
				0.012-0.12 mg/mL in **NS**[66]	16 h RT[64]	
				devices with spikes (e.g., chemo dispensing pins) **may be used** with vials[67]		
PACLitaxel 30 mg/5 mL 100 mg/16.7 mL 150 mg/25 mL 300 mg/50 mL (Hospira) (RT)(PFL) preservative[68]	N/A	6 mg/mL[69]	48 h RT[2,69,70]	0.3-1.2 mg/mL in **NS**, D5W, D5NS, D5LR[69] (e.g., 100-1000 mL)*	complete administration within 27 h RT[69]	- use non-DEHP bag and tubing with 0.22 micron in-line filter[69]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
PACLitaxel, nanoparticle, albumin-bound (nab) 100 mg (Celgene) (RT)(PFL) no preservative[71]	20 mL NS[71] - slowly direct diluent against side of vial (i.e., greater than or equal to 1 min) during reconstitution[71] - let stand for greater than or equal to 5 min to wet powder[71] - gently swirl or invert for greater than or equal to 2 min[71]	5 mg/mL[71]	use immediately (RT) or 8 h F[71] **(PFL)[71]	in empty sterile PVC, non-PVC, or non-DEHP infusion bag[71]	48 h F plus an additional 8 h RT[72]	- each vial contains 900 mg human albumin[71] - to prevent foaming, do NOT inject NS directly onto the powder[71] - some settling may occur; use mild agitation to resuspend[71] - administer using a 15 micron filter ONLY (NOTE:filters with a pore size less than 15 microns may cause filter blockage)[73,74]
Pamidronate 30 mg/10 mL 60 mg/10 mL 90 mg/10 mL (Hospira) (RT) no preservative[75]	N/A	3 mg/mL 6 mg/mL 9 mg/mL[75]	discard unused portion[75]	0.06–0.36 mg/mL **NS**, D5W[75] (e.g., 250 mL* NS)[76]	24 h F followed by 24 h RT (total 48 h)[75] **(PFL)[75]	- do **NOT** mix with calcium containing solution (e.g., Ringer's)[75]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Pamidronate 30 mg/10 mL 60 mg/10 mL 90 mg/10 mL (Omega) (RT) no preservative[77]	N/A[77]	3 mg/mL 6 mg/mL 9 mg/mL[77]	discard unused portion[77]	0.06–0.36 mg/mL **NS**, D5W[77] (e.g., 250 mL* NS)[76]	24 h F followed by 24 h RT (total 48 h)[77] **(PFL)[77]	- do **NOT** mix with calcium containing solution (e.g., Ringer's)[77]
Pamidronate 30 mg/10 mL 60 mg/10 mL 90 mg/10 mL (Fresenius Kabi) (RT) no preservative[78]	N/A	3 mg/mL 6 mg/mL 9 mg/mL[78]	discard unused portion[78]	**NS**; D5W[78] Less than or equal to 0.36 mg/mL[78]	24 h RT[78]	- do **NOT** mix with calcium containing solutions[78]
Pamidronate 30 mg/10 mL 60mg/10 mL 90 mg/10 mL (Sandoz Canada) RT no preservative[79]	N/A	3 mg/mL 6 mg/mL 9 mg/mL[79]	discard unused portion[29,79]	**NS**; D5W[79]	24 h RT[79]	- do **NOT** mix with calcium containing solution (e.g., Ringer's)[79]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
PANitumumab 100 mg/5 mL 400 mg/20 mL (Amgen) (F)(PFL) do not shake no preservative[80]	N/A	20 mg/mL[80]	discard unused portion[80]	Less than or equal to 1000 mg: 100 mL NS[80] Greater than 1000mg: 150 mL NS[80] 1-10mg/mL[80,81]	24 h **F,** 6 h RT[80,81]	- administer with 0.2 or 0.22 micron in-line filter[80] - solution may contain particulates which do not affect product quality[80] - do not administer if discoloured[80]
pegaspargase (PEG-asparaginase) (pegylated asparaginase E. *coli*) 3750 units/5 mL (Baxalta) (F)(PFL) no preservative[82]	N/A	750 units/mL[82]	discard unused portion[82]	IM: max volume: 2 mL in children and adolescents; 3 mL in adults if volume greater than above, use multiple sites[82]	syringe: discard at end of day[2,82]	- discard cloudy solution[82] - do NOT shake[82] - do not use if stored out of refrigerator for greater than 48 h[83] - do not use if previously frozen[83]
				IV: 100 mL **NS,** D5W[82]	bag: complete administration within 48 h F[83] protect bag from direct sunlight during infusion[83]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Pembrolizumab 100 mg/4 mL (Merck) (F)(PFL) do not shake no preservatives[84]	N/A	25 mg/mL[84]	discard unused portion[2,84]	1-10 mg/mL **NS**, D5W[84] mix by gentle inversion[84]	complete administration within 6 h RT, 24 h F[84]	- use a 0.2 to 5 micron in-line filter[84] - allow vials and diluted solutions to come to RT prior to use[84] - vials contain 0.25 mL overfill[84]
Pembrolizumab 50 mg (Merck) (F) no preservative[84]	2.3 mL SWI[84] direct diluent against side of vial during reconstitution to avoid foaming[84] allow up to 5 minutes for bubbles to clear[84] do NOT shake[84]	25 mg/mL[84]	6 h RT, 24 h F[84]	1-10 mg/mL NS, D5W[84] mix by gentle inversion[84]	complete administration within 6 h RT, 24 h F[84]	- use 0.2 to 5 micron in-line filter[85] - allow reconstituted vials and diluted solutions to come to RT prior to use[84] - vials can be at RT for up to 24 h prior to use[84] - vials contain 20% overfill[84]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Pemetrexed 100 mg 500 mg (Eli Lilly) (RT) no preservative[86]	100 mg: 4.2 mL preservative-free NS[86] 500 mg: 20 mL preservative-free NS[86]	25 mg/mL[86]	24 h **F**, RT[86]	100 mL preservative-free NS[86]	24 h **F**, RT[86]	- do **NOT** mix with calcium containing solution (e.g., Ringer's)[87]
PERTuzumab 420 mg/14 mL (Roche) (F)(PFL) no preservative[88]	N/A	30 mg/mL[88] do NOT shake[88]	discard unused portion[2,88]	250 mL NS only[88] mix by gentle inversion to avoid foaming[88]	24 h **F**, RT[88]	- do NOT use dextrose containing solutions[88]
Plerixafor 24 mg/1.2 mL (sanofi-aventis) (RT) no preservative[89]	N/A	20 mg/mL[89]	discard unused portion[89]	SC syringe[89]	48 hours RT[29,90]	
Porfimer 15 mg 75 mg (Axcan) (RT)(PFL) no preservative[91]	15 mg: 6.6 mL D5W[91] 75 mg: 31.8 mL D5W[91] record time of reconstitution	2.5 mg/mL[91]	24 h F **(PFL)[91]	syringe[91]	use within 4 h of initial reconstitution[7,92] **(PFL)[91]	- avoid contact with skin and eyes; protect exposed area from light[91]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Raltitrexed 2 mg (Hospira) (**F**, RT)(PFL) no preservative[93]	4 mL SWI[93]	0.5 mg/mL[93]	24 h **F**, RT[93]	50–250 mL **NS**, D5W[93]	24 h **F**, RT[93]	
Ramucirumab 100 mg/10 mL 500 mg/50 mL (Eli Lilly) (F)(PFL) (do not shake) no preservative[94]	N/A	10 mg/mL[94]	discard unused portion[94]	250 mL* NS[94] (0.4 – 4 mg/mL)[95] gently invert to mix[94] do NOT shake[94]	4 h RT, 24 h F[94]	- use 0.22 micron filter[94] - do NOT use dextrose containing solutions[94]
riTUXimab 100 mg/10 mL 500 mg/50 mL (Roche) (F)(PFL) no preservative[96]	N/A	10 mg/mL[96]	discard unused portion[96]	1-4 mg/mL **NS**, D5W[96] (e.g., 250-500 mL)*	24 h **F**, 12 h RT[97,98]	- once removed from the fridge, compounded product is stable for 12h RT[97,98]
riTUXimab **subcutaneous** 1400 mg/11.7 mL (Roche) (F)(PFL) no preservative[99]	N/A	120 mg/mL[99]	discard unused portion[99]	SC syringe[99]	48 h F plus 8 h RT[99]	- contains hyaluronidase[99]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
romiDEPsin 10 mg (Celgene Inc.) (RT)[100] no preservative[2]	2.2 mL of supplied diluent[100,101] swirl gently to mix[100]	5 mg/mL[100]	8 h RT[100]	500 mL NS[100]	24 h RT[100]	- reconstituted solution will be slightly viscous[102] - vials contain overfill to allow for full drug recovery (drug vial contains 11 mg romidepsin; diluent vial contains 2.4 mL diluent)[100]
Siltuximab 100 mg 400 mg (Janssen) (F)(PFL) no preservative[103]	100 mg: 5.2 mL SWI[103] 400 mg: 20 mL SWI[103] allow vial to come to room temperature prior to use (~30 minutes)[103] gently swirl, do NOT shake[103]	20 mg/mL[103]	2 h RT[103]	250 mL **D5W**[103] dilute to 250 mL final volume by withdrawing volume from bag equal to volume of drug to be added[103]	complete administration within 6 h RT [103]	- use 0.2 micron in-line filter[103]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Streptozocin 1g (Pfizer) (F)(PFL) no preservative[104]	9.5mL **NS**, SWI, D5W[104]	100 mg/mL[104]	48 h F,[104] 24 h RT	syringe[104]	48 h F, 24 h RT[104]	
				50-500 mL* **NS**, D5W, SWI[104]	48 h F, 24 h RT[104]	
Temsirolimus 30 mg/1.2 mL (Wyeth) (F)(PFL)[105,106] no preservative[107]	1.8 mL supplied diluent[105,106]	10 mg/mL[105,106]	24 h RT[105,106] **(PFL)[105]	250 mL NS[105,106]	complete administration within 6 h[105,106]	- use non-DEHP bag and tubing with in-line filter[105,106]
Teniposide 50 mg/5 mL (BMS) (RT) preservative[108]	N/A	10 mg/mL[108]	discard unused portion	50 – 500 mL **NS** or D5W for a final concentration of 0.1-1 mg/mL[108]	0.1-0.4 mg/mL: 24 h RT[108] 1 mg/mL: complete administration within 4 h of preparation RT[108,109]	- do not refrigerate - use non-DEHP bag and tubing[108] - do not use if precipitates[108,109] - contains DMA*** - excessive agitation may cause precipitation[108]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Thiotepa 15 mg (Bedford) (F)(PFL) no preservative[110]	1.5 mL SWI[110] filter through 0.22 micron filter[110] record time of reconstitution	10 mg/mL[110]	8 h F[110]	50 mL* NS[110]	use within 4 h of initial reconstitution[110,111] **(PFL)[110,112]	- do not use if precipitates or remains opaque[110] - do not use for IT injection
				syringe: reconstituted solution is hypotonic and must be further diluted with NS prior to use[110] (final concentration of 0.5-1 mg/ml is nearly isotonic)[113]	use within 4 h of initial reconstitution[110,111] **(PFL)[110,112]	
Thiotepa **<u>IT injection</u>** 15 mg (Bedford) (F)(PFL) no preservative[110]	diluents containing preservatives should **NOT** be used for intrathecal administration 1.5 mL SWI[110] filter through 0.22 micron filter[110] record time of reconstitution	10 mg/mL[110]	8 h F[110]	qs to 6 mL with preservative free NS[114]	use within 4 h of initial reconstitution[110,111] **(PFL)[110,112]	- auxiliary label[26]: "IT" - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag[26] - do not use if precipitates or remains opaque[110]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Thyrotropin alfa 1.1 mg (Genzyme) (F)(PFL) no preservative[115]	1.2 mL SWI[115] swirl contents[115] do NOT shake	0.9 mg/mL[115]	24 h F[115]	syringe[115]	24 h F[115]	
Topotecan 4 mg (Hospira) (F)(PFL) no preservative[116]	N/A	1 mg/mL[116]	discard unused portion[117]	0.02–0.5 mg/mL[116] 50-100 mL **NS**, D5W[117]	24 h **F**, RT[116]	
Topotecan 4 mg (Mylan) (RT)(PFL) no preservative[118]	4 mL SWI[118]	1 mg/mL[118]	24 h **F**, RT[118]	0.02 – 0.5 mg/mL[118] 50-100 mL NS, D5W[118]	24 h **F**, RT[118]	
Topotecan 4 mg/4 mL (Sandoz) (F)(PFL) no preservative[119]	N/A	1 mg/mL[119]	discard unused portion[119]	0.02-0.5 mg/mL 50-100 mL **NS**, D5W[119]	24 h F[119] **(PFL)[119]	

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Trastuzumab (HERCEPTIN®) 440 mg (Roche) (F) preservative[120]	20 mL supplied BWI[120] swirl vial gently; allow to stand undisturbed for 5 min[120]	21 mg/mL[120]	14 d F[2]	250 mL **NS** only[120] do NOT use dextrose containing solutions[120]	24 h **F**, RT[120]	- do NOT shake[120]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Trastuzumab Emtansine (KADCYLA®) 100 mg 160 mg (Roche) (F)(PFL) no preservative[121]	100 mg vial: 5 mL SWI[121] 160 mg vial: 8 mL SWI[121] swirl gently until completely dissolved do NOT shake[121]	20 mg/mL[121]	24 h **F**[121] do NOT freeze[121]	250 mL **NS** or 0.45% sodium chloride only[121] do NOT shake[121]	24 h F[121] do NOT freeze[121]	- do not use if reconstituted solution contains visible particulates or is cloudy or discolored[121] - dextrose 5% solutions cause aggregation of the protein; do not dilute with dextrose containing solutions[121] - use a 0.2 micron in-line filter or 0.22 micron polyethersulfane (PES) filter to administer infusions prepared in NS; filter is optional for solutions in 0.45% NS[121]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
TRC105 (Carotuximab) 100 mg/4 mL 200 mg/8 mL 400 mg/16 mL (Tracon) (F)(PFL) no preservative[122]	N/A	25 mg/mL[122]	discard unused portion[2]	0.6 – 10 mg/mL NS[123] invert gently to mix	complete infusion within 8 h RT, 24 h F[122,123]	- use a 0.2 micron in-line filter for administration[122]
Treosulfan 1 g 5 g (medac) (RT) no preservative[124]	**pre-heat** SWI to 30°C (not higher) **shake vial** carefully before adding the warmed SWI **1 g vial:** 20 mL SWI, while slightly shaking vial and syringe; continue shaking the reconstituted solution for another 2 min[124] **5 g vial:** 100 mL SWI, while slightly shaking vial and syringe; continue shaking the reconstituted solution for another 2 min[124]	50 mg/mL[124]	48 h RT[7,124]	undiluted[125] dilute with **NS** or D5W in empty infusion bag for final concentration = 20 mg/mL[124]	48 h RT[7,124]	- compatible with polytetrafluoroethylene filters[124] - may require vigorous shaking to reconstitute[124]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
vinBLAStine 10 mg/10 mL (Hospira) (F)(PFL) no preservative[126]	N/A	1 mg/mL[126]	discard unused portion[126]	25-50 mL **NS**, D5W[127]	24 h **F**, RT[128,129]	- auxiliary label: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[130,131]
vinBLAStine 10 mg/10 mL (Teva) (F)(PFL) no preservative[132]	N/A	1 mg/mL[132]	discard unused portion[132]	25-50 mL **NS**, D5W[127,133]	use within 4 h of initial puncture[2]	- auxiliary label: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[130,131]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
vinCRIStine 2 mg/2 mL 5 mg/5 mL (Hospira) (F)(PFL) no preservative[134]	N/A	1 mg/mL[134]	8 h **F**, RT[134]	50 mL* **NS**, D5W[134]	24 h F, 6 h RT[134] **(PFL)[134]	- auxiliary label: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[130,131] - for ULYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing etoposide, DOXOrubicin, vinCRIStine)

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
vinCRIStine 1 mg/1 mL 2 mg/2 mL 5 mg/5 mL (Teva) (F)(PFL) no preservative[135]	N/A	1 mg/mL[135]	8 h **F**, RT[135]	0.01-0.1 mg/mL **NS,** D5W[135] 25-50 mL **NS**, D5W[136]	24 h F, RT[135]	- auxiliary label: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[130,131] - for ULYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing etoposide, DOXOrubicin, vinCRIStine)
Vinorelbine 10 mg/1 mL 50 mg/5mL (Fresenius Kabi) (F)(PFL) no preservative[137]	N/A	10 mg/mL[137]	discard unused portion[137]	0.5-2.0 mg/mL[137] **NS**, D5W, ½NS, D5½NS, Ringer's, Ringer's Lactate[137]	24 h **F**, RT[137]	- auxiliary label: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[130,131]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Vinorelbine 10 mg/1 mL 50 mg/5 mL (Hospira) (F)(PFL) no preservative[138]	N/A	10 mg/mL[138]	discard unused portion[138]	0.5–2.0 mg/mL[138] 50 mL* **NS**, D5W, ½NS, D5½NS, Ringer's, Ringer's Lactate[138]	24 h **F**, RT[138]	- auxiliary label: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[130,131]
Vinorelbine 10 mg/1 mL 50 mg/5 mL (Teva) (F)(PFL) no preservative[139]	N/A	10 mg/mL[139]	discard unused portion[139]	0.5–2.0 mg/mL[139] 50 mL* **NS**, D5W, ½NS, D5½NS, Ringer's, Ringer's Lactate[139]	24 h **F**, RT[139]	- auxiliary label: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES[130,131]
Zoledronic acid 4 mg/5 mL (Dr Reddy's) (RT) no preservative[140]	N/A	0.8 mg/mL[140]	discard unused portion[140]	100 mL **NS**, D5W[140]	complete infusion within 24 h of preparation[140] **Refrigerate** diluted product if not used immediately after preparation; bring to RT prior to administration[140]	- do **NOT** mix with calcium containing solutions[140]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product**	**Product Stability**	**Special Precautions/Notes**
Zoledronic acid (ZOMETA) 4 mg/ 5 mL (Novartis) (RT) no preservative[141]	N/A	0.8 mg/ mL[141]	discard unused portion[2]	100 mL **NS,** D5W[141]	complete infusion within 24 h of preparation[141] **Refrigerate** diluted product if not used immediately after preparation; bring to RT prior to administration[141]	- do NOT mix with calcium containing solutions[141]
Zoledronic acid 4 mg/5 mL (Sandoz) (RT) no preservative[142]	N/A	0.8 mg/mL[142]	discard unused portion[142]	100 ml **NS**, D5W[142]	complete infusion within 24 h of preparation[142] Refrigerate diluted product if not used immediately after preparation; bring to RT prior to administration[142]	- do NOT mix with calcium- or other divalent cation-containing infusion solutions (e.g., Lactated Ringer's)[142]

* Suggested volume based on usual dose range and any concentration range of stability data
** Protect from light means minimizing exposure to direct sunlight over a *storage* period. More specific information on protection from light (eg, protecting container and tubing during *administration*) will be indicated in the Under the Special Precautions/Notes column.
*** Contains DMA (N,N dimethylacetamide). Product may be incompatible with closed system transfer devices such as ChemoLock.

Centres are not to change the content locally but should forward suggestions to the Cancer Drug Manual staff.

Explanatory Notes

Stability data assumes products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to the classification outlined in USP 797.[143,144]
Vial stability: Stability of solution after first puncture or reconstituted solution.
Storage temperature: If information states same stability with refrigerator and room temperature storage, then fridge stability is bolded as preferred (ie, to minimize growth of micro-organisms).
Discard unused portion: Unused portion from single use vials should be discarded at the end of the day.
"overfill known" is stated if the manufacturer states overfill that is present is within acceptable limits.
"Complete administration within __" is stated if the manufacturer specifies that the infusion must be completed in a specific time frame following preparation, usually including entire time required for preparation (from first puncture), storage, and administration of infusion.

Abbreviations

BWI = bacteriostatic water for injection
CIVI: ambulatory pump = Continuous Intravenous Infusion (e.g., elastomeric infusor)
D5W = dextrose 5% in water
DMA = N,N dimethylacetamide
F = refrigerate
Non-DEHP = not containing Di(2-ethylhexyl) phthalate (DEHP)
NS = normal saline
PFL = protect from light
RT = room temperature
SWI = sterile water for injection

References

1. Hospira Healthcare Corporation. LEUCOVORIN CALCIUM INJECTION® product monograph. Saint-Laurent, Quebec; 7 June 2007.
2. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September 2007.
3. John Korontzis. Personal communication. Regulatory Affairs Associate, Leucovorin Calcium, Mayne Pharma Canada; February 2005.
4. The United States Pharmacopeial Convention, Inc. General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2003.
5. Teva Canada Limited. Leucovorin calcium injection® product monograph. Toronto, Ontario; 5 May 2014.
6. Novopharm Limited (Teva). LEUCOVORIN CALCIUM® Injection product information package. Toronto, Ontario; undated.
7. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6 January 2006.
8. Jenny Yeung. Personal communication. Medical Information Specialist, Teva Canada; 12 April 2017.
9. Pfizer Canada Inc. Leucovorin calcium injection product monograph. Kirkland, Quebec; 21 June 2018.
10. Ovation Pharmaceuticals Inc. MUSTARGEN® Package Insert. Deerfield, Illinois; October 2005.
11. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005.
12. Trissel LA. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2003.
13. GlaxoSmithKline Inc. Alkeran Package Insert. Mississauga, Ontario; Montreal, Quebec; 2004.
14. Pharmaceutical Partners of Canada Inc. Mesna Package Insert. Richmond Hill, Ontario; November 2001.

15. Mayne Pharma Canada. Methotrexate Product Monograph. Montreal, Quebec; December 2003.
16. John Korontzis. Personal communication. Regulatory Affairs Associate, Methotrexate, Mayne Pharma Canada; February 2005.
17. John Korontzis. Personal communication. Regulatory Affairs Associate, Fluorouracil, Methotrexate, Vincristine, Mayne Pharma Canada; 14 March 2005.
18. BC Cancer Agency Miscellaneous Origins Tumour Group. (MOHDMTX) BCCA Protocol Summary for Treatment of Meningeal Disease (Miscellaneous Tumour Origins) using High Dose Methotrexate with Leucovorin Rescue. Vancouver, British Columbia: BC Cancer Agency; 1 Jan 2013.
19. BC Cancer Agency Sarcoma Tumour Group. (SAHDMTX) BCCA Protocol Summary for Treatment of Osteosarcoma Using High Dose Methotrexate with Leucovorin Rescue. Vancouver, British Columbia: BC Cancer Agency; 1 Nov 2012.
20. BC Cancer Agency Lymphoma Tumour Group. (LYHDMRP) BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and riTUXimab. Vancouver, British Columbia: BC Cancer Agency; 1 Jun 2014.
21. BC Cancer Agency Lymphoma Tumour Group. (LYHDMTXP) BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 1 Jun 2014.
22. BC Cancer Agency Lymphoma Tumour Group. (LYHDMTXR) BCCA Protocol Summary for Treatment of Leptomeningeal Lymphoma or Recurrent Intracerebral Lymphoma with High Dose Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 1 Jun 2014.
23. Hospira Healthcare Corporation. Methotrexate Injection USP® product monograph. Saint-Laurent, Quebec; 27 June 2012.
24. Trissel's®2 IV Compatibility (database on the Internet). Methotrexate sodium. Thomson Reuters MICROMEDEX® 2.0, updated periodically. Available at: http://www.micromedex.com. Accessed 9 March 2015.
25. BC Cancer Agency. Pharmacy Policy Number III-50-02: Methotrexate Intrathecal Injection. Vancouver, British Columbia: BC Cancer Agency; 27 January 2006.
26. BC Cancer Agency Miscellaneous Origin Tumour Group. BCCA protocol summary for solid tumours using intrathecal methotrexate and/or thiptepa and/or cytarabine (MOIT). Vancouver, British Columbia: BC Cancer Agency; 1 July 2005.
27. BC Cancer Agency. Systemic Therapy Policy III-50: Administration of Cytotoxic Drugs by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir. Vancouver, British Columbia; 31 October 2002.
28. Hospira Healthcare Corporation. Methotrexate Injection USP product monograph. Saint-Laurent, Quebec; 05 May 2009.
29. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September 2007.
30. Accord Healthcare Inc. Mitomycin product monograph. Kirkland, Quebec; 7 June 2017.
31. Au JLS, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93(8):597-604.
32. Jessie LS Au PharmD PhD. Personal communication. Distinguished University Professor, The Ohio State University; 14 May 2007.
33. Myers AL, Zhang Y, Kawedia JD, et al. Solubilization and stability of mitomycin C solutions prepared for intravesical administration. Drugs R D 2017;17:297-304.
34. Teva Canada Limited. Mitomycin for injection® product monograph. Toronto, Ontario; 30 June 2017.
35. Fresenius Kabi Canada Ltd. Mitoxantrone injection® product monograph. Richmond Hill, Ontario; 28 September 2016.
36. Hospira Healthcare Corporation. Mitoxantrone Injection, USP Product Monograph. Saint-Laurent, Quebec; 13 June 2007.
37. Novopharm Limited. Mitoxantrone Injection Product Monograph. Toronto, Ontario; 19 May 2005.
38. Angie Chan. Personal communication. Drug Information Pharmacist, Novopharm; 7 Mar 2008.
39. Bristol-Myers Squibb Canada. OPDIVO® product monograph. Montreal, Quebec; 24 September 2015.
40. Bristol-Myers Squibb Canada. OPDIVO® product monograph. Montreal, Quebec; 12 May 2017.
41. Hoffmann-La Roche Ltd. GAZYVA® product monograph. Mississauga, Ontario; 21 December 2015.
42. Anna Sivojelezova MSc. Personal communication. Drug Information Associate; Hoffmann-La Roche Ltd Drug Information; 24 April 2015.
43. Omega Laboratories Ltd. Octreotide Acetate Injection product monograph. Montreal, Quebec; 23 July 2010.
44. Novopharm Limited. Octreotide Injection Product Monograph. Scarborough, Ontario; 15 March 2007.
45. Novartis Pharmaceuticals Canada Inc. SANDOSTATIN® Product Monograph. Dorval, Quebec; 9 January 2001.
46. Repchinsky C, editor. Sandostatin LAR monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2005. p. 1912-1916.
47. Repchinsky C editor. Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004.
48. Vancouver Hospital and Health Sciences Centre Pharmacy Department. Octreotide. Parenteral drug therapy manual. Vancouver, BC; February 2002.
49. GlaxoSmithKline. Guidance Booklet: compassionate use access of ofatumumab for patients with chronic lymphocytic leukemia (CLL) who are refractory to fludarabine and alemtuzumab or who are deemed inappropriate for alemtuzumab therapy. version 5; 1 February 2010.

50. Eli Lilly Canada Inc. LARTRUVO® product monograph. Toronto, Ontario; 23 November 2017.
51. Actavis Pharma Company. ACT Oxaliplatin® product monograph. Mississauga, Ontario; 1 June 2015.
52. Pfizer Canada Inc. Oxaliplatin injection product monograph. Kirkland, Quebec; 31 May 2017.
53. Sandoz Canada Inc. Oxaliplatin injection product monograph. Boucherville, Quebec; 12 August 2015.
54. Medical Information. Personal communication. Pfizer Canada Inc.; 6 June 2017.
55. sanofi-aventis Canada Inc. ELOXATIN® product monograph. Laval, Quebec; 13 January 2009.
56. Eiden C, Philibert L, Bekhtari K, et al. Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags. Am J Health Syst Pharm 2009;66.
57. Andre P, Cisternino S, Roy A-, et al. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. American Journal of Health-System Pharmacy 2007;64(18):1950-1954.
58. Katryn Vosburg. Personal communication. Drug Information & Pharmacovigilance Specialist, Sandoz Canada Inc.; 26 February 2016.
59. Teva Canada Limited. Teva-Oxaliplatin injection® product monograph. Toronto, Ontario; 11 September 2015.
60. Accord Healthcare Inc. Paclitaxel injection product monograph. Markham, Ontario; 13 August 2012.
61. Claude Mercure. Personal communication. Production Manager Biolyse Pharma Corporation; 21 December 2009.
62. Biolyse. PACLITAXEL FOR INJECTION® product monograph. St. Catherines, Ontario; 2 December 2005.
63. Claude Mercure. Personal communication. Manager, Biolyse Pharma Corporation; 24 June 2014.
64. Zeng Z, Lazakovitch E. Study IR 120: Physical and Chemical Stability Study of Paclitaxel for Injection in 0.9 % Sodium Chloride in concentration range 0.012-0.12 mg/mL. Biolyse Pharma March 2010.
65. Mercure C. Stability of 0.1 mg/mL of paclitaxel for injection in sodium chloride (0.9%) solution. St Catharines, Ontario: Biolyse Pharma; 2 February 2007.
66. Xu Q, Trissel LA, Martinez JF. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C. Am J Hosp Pharm 1994;51(24):3058-60.
67. Lisa Tavano. Personal communication. Biolyse Pharma Corporation; 14 May 2012.
68. Robyn Mackenzie. Personal communication. Hospira Healthcare Corporation; 4 April 2012.
69. Hospira Healthcare Corporation. PACLITAXEL FOR INJECTION® product monograph. Saint-Laurent, Quebec; 1 September 2009.
70. Rose Toussaint. Personal communication. Hospira Canada Healthcare Corporation; 4 April 2012.
71. Celgene Inc. ABRAXANE® product monograph. Mississauga, Ontario; 24 July 2014.
72. Aisling Cahill. Drug Safety and Medical Information Specialist. Personal communication. Celgene Inc.; 23 April 2015.
73. Celgene Europe Limited. ABRAXANE® product monograph. Uxbridge, UK; 11 January 2013.
74. Celgene Inc. ABRAXANE® product monograph. Mississauga, Ontario; 18 January 2016.
75. Mayne Pharma (Canada) Inc. Pamidronate Package Insert. Montreal, Quebec; 2002.
76. BC Cancer Agency Breast Tumour Group. BCCA protocol summary for treatment of acute bone pain secondary to breast cancer metastases using pamidronate or IV clodronate (BRAVPAM). Vancouver, British Columbia: BC Cancer Agency; 1 May 2001.
77. Omega Laboratories Ltd. Pamidronate Disodium product monograph. Montreal, Quebec; 06 June 2005.
78. Pharmaceutical Partners of Canada. Pamidronate Disodium For Injection product monograph. Richmond Hill, Ontario; 18 January 2010.
79. Sandoz Canada Inc. Pamidronate injection product monograph. Boucherville, Quebec; 28 February 2006.
80. Amgen Canada. VECTIBIX® product monograph. Mississauga, Ontario; 5 March 2009.
81. Diane Lord. Personal communication. Amgen Canada Inc Medical Information Department; 19 June 2009.
82. Baxalta Canada Corporation. ONCASPAR® product monograph. Mississauga, Ontario; 24 February 2017.
83. Baxalta US Inc. ONCASPAR® product monograph. Cambridge, Massachusetts, USA; 24 February 2017.
84. Merck Canada Inc. KEYTRUDA® product monograph. Kirkland, Quebec; 21 February 2018.
85. Merck Canada Inc. KEYTRUDA® product monograph. Kirkland, Quebec; 5 February 2016.
86. Eli Lilly Canada. Pemetrexed product information. Toronto, Ontario; 2008.
87. Eli Lilly Canada Inc. ALIMTA® Product Monograph. Toronto, Ontario; 21 May 2004.
88. Hoffmann-La Roche Limited. PERJETA® product monograph. Mississauga, Ontario; 12 April 2013.
89. sanofi-aventis Canada Inc. MOZOBIL® product monograph. Laval, Quebec; 8 October 2014.
90. Maureen Coughlin BSc Pharm. Personal communication. Solutions in Health Inc. acting as an authorized agent of sanofi-aventis; 24 May 2017.
91. Axcan Pharma Inc. Photofrin Package Insert. Mont-Saint-Hilaire, Quebec; 2004.

92. Marie-Helene Doyon B.Pharm. M.Sc. Personal communication. Medical Information Specialist, Porfimer, Axcan Pharma. 3 March 2005.
93. Hospira Healthcare Corporation. TOMUDEX® product monograph. Saint-Laurent, Quebec; 23 April 2008.
94. Eli Lilly Canada Inc. CYRAMZA® product monograph. Toronto, Ontario; 16 July 2015.
95. Marilyn Bain BScN. Personal communication. Senior Medical Information Associate, Eli Lilly Canada, Inc.; 16 January 2017.
96. Hoffmann-La Roche Ltd. RITUXAN® product monograph. Mississauga, Ontario; 29 March 2012.
97. Hoffmann-La Roche Ltd. RITUXAN® product monograph. Mississauga, Ontario; 29 May 2014.
98. Diana Fung pharmacist. Personal communication. Hoffmann-La Roche Medical Information; 16 July 2014.
99. Hoffmann-La Roche Ltd. RITUXAN® SC product monograph. Mississauga, Ontario; 9 September 2016.
100. Celgene Inc. ISTODAX® product monograph. Mississauga, Ontario; 13 December 2016.
101. Celgene Inc. INFO Rx ISTODAX® (romidepsin) for Injection. Mississauga, Ontario; 10 July 2017.
102. Aisling Cahill, Drug Safety and Medical Information Specialist. Personal communication. Celgene Inc.; 17 July 2015.
103. Janssen Inc. SYLVANT® product monograph. Toronto, Ontario; 6 January 2016.
104. Pharmacia Canada Inc. Zanosar Package Insert. Mississauga, Ontario; March 2003.
105. Wyeth Canada. TORISEL® product monograph. Montreal, Canada; 16 October 2008.
106. McEvoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. p. 1226-1228.
107. Anna Sivojelezova M.Sc. Personal communication. Medical Information Associate, Wyeth. 6 January 2010.
108. Bristol-Myers Squibb Canada. VUMON® product monograph. St. Laurent, Quebec; 26 October 2004.
109. Trissel's®2 IV Compatibility (database on the Internet). Teniposide. Thomson Reuters MICROMEDEX® 2.0, updated periodically. Available at: http://www.micromedex.com. Accessed 27 April 2011.
110. Bedford Laboratories™. Thiotepa for Injection USP Package Insert. Bedford, Ohio; April 2001.
111. Solimando D.A. Updates of melphalan and thiotepa. Hosp Pharm 1997;32(8):1082-1088.
112. Christina Hsu Pharm. D. Personal communication. Bedford Laboratories Professional Services Department; 29 August 2008.
113. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; 2005. p. 1395-1403.
114. BC Cancer Agency Miscellaneous Origin Tumour Group. (MOIT) BCCA Protocol Summary for Soild Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine. Vancouver, British Columbia: BC Cancer Agency; 1 July 2005.
115. Genzyme Canada. Thyrogen Product Monograph. Mississauga, Ontario; 2004.
116. Hospira Healthcare. Topotecan Hydrochloride for Injection product monograph. Saint-Laurent, QC; 22 June 2012.
117. Hospira Healthcare Corporation. Topotecan hydrochloride for injection product monograph. Saint-Laurent, Quebec; 26 August 2014.
118. Mylan Pharmaceuticals ULC. Topotecan hydrochloride for injection product monograph. Etobicoke, Ontario; 18 February 2015.
119. Sandoz Canada Inc. Topotecan injection product monograph. Boucherville, Quebec; 5 September 2014.
120. Hoffman-La Roche Limited. HERCEPTIN® product monograph. Mississauga, Ontario; 16 November 2012.
121. Hoffmann-La Roche Limited. KADCYLA® product monograph. Mississauga, Ontario; 11 September 2013.
122. Tracon Pharmaceuticals Inc. TRC105 (carotuximab) investigational brochure. San Diego, California; 14 February 2017 (version 10.0).
123. Tracon Pharmaceuticals Inc. Clincial Protocol: A Phase 2A Study of TRC105 (with Option to Add Bevacizumab) in Patients with Refractory Gestational Trophoblastic Neoplasia (GTN). San Diego, California; 20 September 2016 Amendment #3.
124. medac UK. TREOSULFAN injection® product monograph. Hamburg, Germany; 24 June 2008.
125. Henrik Fenger. Personal communication. Management Assiciate, International Division medac; 03 March 2010.
126. Mayne Pharma (Canada) Inc. Vinblastine product monograph. Kirkland, Quebec; 10 August 2003.
127. Lexi-Drugs® (database on the Internet). VinBLAStine. Lexi-Comp Inc., 3 November 2014. Available at: http://online.lexi.com. Accessed 20 November 2014.
128. Jan Barrow. Personal communication. Supervisor, Hospira Canada Clinical Support. Saint-Laurent, Quebec; 03 December 2007.
129. Tanya Leduc. Personal communication. Acting editor, BC Cancer Agency Cancer Drug Manual; 18 Dec 2007.
130. World Health Organization. Information Exchange System: Alert No. 115 (QSM/MC/IEA.115). Geneva, Switzerland: World Health Organization; 18 July 2007.
131. BCCA Provincial Systemic Therapy Program. Labeling of vinca alkaloid syringes. Policy # V-40. Vancouver, British Columbia: BC Cancer Agency; 27 May 1999.
132. Teva Canada Limited. Vinblastine sulfate injection® product monograph. Toronto, Ontario; 1 February 2013.
133. Trissel's®2 IV Compatibility (database on the Internet). Vinblastine sulfate. Thomson Reuters MICROMEDEX® 2.0, updated periodically. Available at: http://www.micromedex.com. Accessed 8 June 2015.

134. Mayne Pharma (Canada) Inc. Vincristine Package Insert. Montreal, QC; Undated.
135. Teva Canada Limited. Vincristine sulfate injection® product monograph. Scarborough, Ontario; 27 March 2014.
136. Lexi-Drugs® (database on the Internet). VinCRIStine. Lexi-Comp Inc., 3 June 2015. Available at: http://online.lexi.com. Accessed 9 June 2015.
137. Pharmaceutical Partners of Canada. Vinorelbine Injection product monograph. Richmond Hill, Ontario; 15 January 2008.
138. Mayne Pharma (Canada) Inc. Vinorelbine Product Monograph. Montreal, QC; Undated.
139. Teva Canada Limited. Vinorelbine tartrate for Injection product monograph. Toronto, Ontario; 20 March 2014.
140. Innomar Strategies Inc. (for Dr. Reddy's Laboratories Limited). Zoledronic acid for injection concentrate® product monograph. Oakville, Ontario; 11 March 2015.
141. Novartis Pharmaceuticals Canada Inc. ZOMETA® product monograph. Dorval, Quebec; 26 July 2013.
142. Sandoz Canada Inc. Zoledronic Acid - Z® product monograph. Boucherville, Quebec; 02 December 2016.
143. The United States Pharmacopeia (USP). General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2004.
144. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5.